InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,186.38
(
1.20%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.19
(
-1.27%
)
Bitcoin
61,890.37
(
2.70%
)
Post# of 252343
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119913
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Summer2762 post# 175362

Monday, 04/28/2014 8:54:39 PM

Monday, April 28, 2014 8:54:39 PM

Post# of 252343
OGXI/TEVA—Custirsen fails phase-3 trial in mCRPC:

http://www.sec.gov/Archives/edgar/data/818686/000130901414000280/exhibit1.htm

…the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival (OS) in men with metastatic CRPC, compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p-value 0.207).

OGXI was down 60% today.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up